The main objectives of these studies were to Oxysophocarpine determine the effects on the Gaucher disease processes 
of imig and vela treatments, and to directly compare the molecular differences elicited by these two highly similar ERTs. The comparisons of the results with both platforms and analytic approaches also highlighted their advantages/disadvantages in identifying the DEGs profiles. To validate the DEGs obtained from the microarray platform, mRNA-Seq was performed on the identical samples and analyzed by two different statistical methods. The analyses of the mRNA from the treated 9V/null mice are referenced to WT transcriptomes, which provided insight into the ERT effects on the diseaserelated molecular events. The mRNA-Seq and the microarray outputs are different; the former are discrete intensities of the read counts, while the latter are continuous intensity distributions. To perform correlations between the DEGs patterns from the two platforms, common sets of genes were selected, which were above the detectable threshold and common to both the platforms. Using these criteria, 17,157 genes were identified. The correlations between the microarray and the mRNA-Seq data were assessed with the log-transformed values of the number of sequence reads mapped to each gene on the Xaxis with the corresponding log-transformed intensity values on the Y-axis. With improvement in technologies and analysis algorithms, microarray and mRNA-Seq hold great promise to reveal deeper insights into the fundamentals of gene expression variations in disease states and between therapeutics. mRNA-Seq platforms have several advantages compared with microarray, chief among which is its greater dynamic/detection range, particularly at low expression levels. Here, two different analytical methods were applied in the analyses of mRNA-Seq data and compared with that from cDNA microarrays. These studies were designed to understand the molecular effects of Gaucher disease and of two biosimilar ERTs on the disease processes in different tissues and to compare the different platforms and statistical approaches to their analyses. An unexpected result was the transcriptomic effect differences between the two biosimilars, imig and vela since they differ by only a few mannosyl residues on their N-linked oligosaccharides. By direct comparison of these two Chlorhexidine hydrochloride biosimilars without any normalization to the WT or saline-treated 9V/null mice, differences were clearly evident in the transcriptomes. The molecular differences imply differential mechanisms and molecular pathways in the therapeutic responses of Gaucher disease to these two biopharmaceuticals. mRNA-Seq allows a comprehensive evaluation and quantification of all subtypes of RNAs in cells or tissues. mRNA-Seq technology can detect transcripts expressed at low levels and permits the identification of unannotated transcripts and new spliced isoforms. Previous transcriptomic studies using microarray relied on hybridization-based technologies, which were probe-based with limitations in detection range due to background noise and signal saturation. This approach also was limited to the catalogue of molecules represented by the probes and prespecified targets. The cross-hybridization and detection levels that effect the accuracy of microarray gene expression estimations are not relevant to mRNA-Seq. Several studies have compared mRNA-Seq and microarray. These include the proof of principal of the NGS platforms and analyses methodology development. Several comparison studies of mRNA-Seq and microarrays have addressed different biological questions.